Dr. Raghava Reddy Levaka Veera

About Raghava Reddy Levaka Veera

Education:

• Obtained MD from Kakatiya Medical College, Warangal, India (2009).
• Completed Residency in Internal Medicine at Geisinger Medical Center, Danville, PA (2015-2018).
• Undertook Fellowship in Hematology/Oncology at Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, PA (2018-2021).

Experience:

• Currently affiliated with Geisinger Wyoming Valley/Henry Cancer Center.

Area of expertise

Affiliated Hospitals

Geisinger Wyoming Valley/Henry Cancer Center

Geisinger Medical Center

Clinical Trials Raghava Reddy Levaka Veera is currently running

Pembrolizumab + Olaparib

for Pancreatic Cancer

This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.

Recruiting1 award Phase 237 criteria

Letrozole +/- Chemotherapy

for Ovarian Cancer

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.

Recruiting2 awards Phase 318 criteria

More about Raghava Reddy Levaka Veera

Other Doctors you might be interested in

Frequently asked questions